Notice of AGM - Correction

13 June 2022

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Notice of Annual General Meeting - Correction

Following the announcement made on 7 June 2022 giving notice of the Annual General Meeting (the "AGM") of the Company to be held on 30 June 2022, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the AGM (the "Notice") and form of proxy, it has come to the attention of the Company that the Notice contains a typographical error.

The explanatory notes at paragraph 2 contained on page 7 of the Notice incorrectly states that "Pursuant to regulation 41 of the Uncertificated Securities Regulations 2001 (as amended) and paragraph 18(c) of the Companies Act 2006 (Consequential Amendments) (Uncertificated Securities) Order 2009, the Company specifies that only those members registered on the Company's register of members at close of business on 27 June 2022 shall be entitled to attend, speak and vote at the Annual General Meeting (or if the meeting is adjourned, those members registered on the register of members of the Company not later than 48 hours before the time fixed for the adjourned meeting).". The Notice should instead state that "…the Company specifies that only those members registered on the Company's register of members at 10am on 28 June 2022 shall be entitled to attend, speak and vote at the Annual General Meeting (or if the meeting is adjourned, those members registered on the register of members of the Company not later than 48 hours before the time fixed for the adjourned meeting).".

As this was a clerical error, no new Notice will be posted to shareholders; however, a copy of the corrected Notice is available on the following page of the Company's website:

 https://www.roquefortplc.com/category/shareholder-documents/

-Ends-

Enquiries:

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is a pre-clinical biotech company focused on developing first in class Midkine targeting drugs for the treatment of cancer.

Through extensive research resulting in validation through publication in over 1,000 scientific journals, Roquefort Therapeutics has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Roquefort Therapeutics holds an exclusive licence to the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Roquefort Therapeutic's pre-clinical program is currently underway with an initial focus on cancer.